Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) filed this Form 8-K on June 18, 2021, to report the results of its 2021 Annual Meeting of Stockholders. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The filing reports the successful adoption of two proposals at the Annual Meeting:
- Director Elections: Paul A. Friedman, M.D., and David Bonita, M.D., were elected as Class I Directors for three-year terms expiring in 2024.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting results.
Investor Verification Checklist
- Verify the vote tallies for the newly elected directors (Paul A. Friedman and David Bonita) against the total shares outstanding.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2021 fiscal year.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K does not include financial metrics.